Effects of adiponectin, plasma D-dimer, inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer

Background To investigate the effects of adiponectin (ADPN), plasma D-dimer (D-D), inflammation, and tumour markers on clinical characteristics and prognosis of patients with ovarian cancer. Methods A total of 80 patients with ovarian cancer treated in our hospital from April 2017 to November 2019 were enrolled as study subjects and evenly divided into an observation group (patients with ovarian cancer) and a control group (patients with the benign ovarian tumour) based on the results of the postoperative pathological biopsy. The levels of ADPN, plasma D-D, inflammatory factors, and serum tumour markers carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4), and risk of ovarian malignancy algorithm (ROMA) were compared between the two groups. The diagnostic value of serum tumour markers CA125, HE4, and ROMA in ovarian cancer was explored. The correlations of ROMA changes with the changes in the levels of ADPN, plasma D-D, high-sensitivity C-reactive protein (hs-CRP), CA125, and HE4 were analysed. Additionally, the related risk factors affecting the development of ovarian cancer were subjected to univariate and multivariate logistic regression analyses. Results In comparison with the control group, the observation group exhibited a lowered ADPN level (p<0.05), notably raised levels of plasma D-D, inflammatory factors hs-CRP and interleukin-6 (IL-6) and serum tumour markers CA125 and HE4 and an evidently increased ROMA (p<0.05). Besides, the detection of serum ROMA showed the highest specificity and sensitivity and low false-positive rate and false-negative rate. The changes of ROMA were positively correlated with the changes in the levels of plasma D-D, hs-CRP, CA125, and HE4 (p<0.05) and negatively associated with the changes in ADPN level (p<0.05). The results of the univariate analysis showed that abnormal ADPN, D-D, hs-CRP, IL-6, CA125, and HE4 levels were related to risk factors affecting the development of ovarian cancer. It was found through multivariate logistic regression analysis that decreased ADPN level and increased D-D, hsCRP, IL-6, CA125, and HE4 levels were independent risk factors affecting the development of ovarian cancer. Conclusions In the case of ovarian cancer, the ADPN level declines, while the levels of plasma D-D, inflammatory factors, and serum tumour markers CA125, HE4, and ROMA rise obviously. Besides, the ROMA level displays a positive relation to the content of CA125, HE4, plasma D-D, and inflammatory factors and a negative association with the ADPN level.

[1]  J. Taube,et al.  Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd–3rd, 2020, Italy) , 2021, Journal of Translational Medicine.

[2]  Scott Christley,et al.  Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma , 2020, PloS one.

[3]  Hengrui Zhu,et al.  PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications , 2020, Molecular Cancer.

[4]  Jasmine Coles,et al.  Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53. , 2020, Cancer biomarkers : section A of Disease markers.

[5]  S. Singhal,et al.  Uterine tumor resembling ovarian sex cord tumor: A series of six cases displaying varied histopathological patterns and clinical profiles , 2020, Indian journal of pathology & microbiology.

[6]  Loretta Auvil,et al.  Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer , 2020, PloS one.

[7]  Y. Barenholz,et al.  An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics. , 2020, Nanoscale.

[8]  Eukesh Ranjit,et al.  Clinician Beware, Giant Ovarian Cysts are Elusive and Rare , 2020, Cureus.

[9]  Liming Wang,et al.  Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses , 2020, Bioengineered.

[10]  I. Park,et al.  Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status , 2019, Journal of breast cancer.

[11]  Shruti Jain,et al.  A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer. , 2019, Gynecologic oncology.

[12]  J. Rao,et al.  Biomarkers that may predict response to immunotherapy in ovarian malignancies. , 2019, Current opinion in obstetrics & gynecology.

[13]  G. Hartmann,et al.  High RIG‐I expression in ovarian cancer associates with an immune‐escape signature and poor clinical outcome , 2019, International journal of cancer.

[14]  J. Hopper,et al.  Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium , 2019, Cancer Epidemiology, Biomarkers & Prevention.

[15]  S. Modesitt,et al.  When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors , 2019, Southern medical journal (Birmingham, Ala. Print).

[16]  S. Sakurai,et al.  C-Mannosyl tryptophan increases in the plasma of patients with ovarian cancer , 2019, Oncology letters.

[17]  Jie Chen,et al.  VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer , 2019, Cancer Immunology, Immunotherapy.

[18]  R. Nomelini,et al.  Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies , 2019, Journal of cancer research and therapeutics.

[19]  P. Ascierto,et al.  Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge 2018” (28–29 November, 2018, Naples, Italy) , 2018, Journal of Immunotherapy for Cancer.

[20]  R. Pilka,et al.  New serum tumor markers S100, TFF3 and AIF-1 and their possible use in oncogynecology. , 2019, Ceska gynekologie.

[21]  G. Turashvili,et al.  Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases. , 2018, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.